Shares in Danish diabetes giant Novo Nordisk (NOV: N) have risen sharply after positive top-line data were announced from the SELECT cardiovascular outcomes trial.
The study compares treatment with 2.4mg of injectable semaglutide with placebo, as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACE).
Approved in the USA for the treatment of obesity, where it is marketed as Wegovy, the GLP-1 agonist appears to offer a range of benefits connected with its role as a weight loss drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze